Literature DB >> 36253995

Effects of tissue plasminogen activator on medium-term functional independence: A propensity score-matched analysis.

Tomohiro Kakinuma1, Takaaki Fujita2, Tetsuya Iwamoto3, Tsuyoshi Mizushiri4, Yukako Yazawa5.   

Abstract

This study revealed the effects of tissue plasminogen activator (tPA) on medium-term functional independence in patients with stroke. We retrospectively examined 240 patients from April 2016 to March 2019 and selected 68 who met our criteria. After adjusting the functional status at the onset by propensity score matching, the functional independence measure (FIM) on admission to and discharge from the convalescent rehabilitation wards was compared between the groups classified by the presence or absence of tPA. Twelve pairs were derived by propensity score matching. Upon admission to the convalescent rehabilitation ward, the median score of the FIM was significantly higher in the tPA group than in the non-tPA group (P = .028). Patients in the tPA group had higher median FIM scores at discharge than those in the non-tPA group (P = .060). The difference in the independence level of activities of daily living (ADL) between the groups with and without tPA may gradually decrease with continuous inpatient rehabilitation. However, the tPA group tended to have high levels of independence in ADL at the time of discharge.
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36253995      PMCID: PMC9575812          DOI: 10.1097/MD.0000000000031108

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  26 in total

1.  Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS).

Authors:  Jyoji Nakagawara; Kazuo Minematsu; Yasushi Okada; Norio Tanahashi; Shinji Nagahiro; Etsuro Mori; Yukito Shinohara; Takenori Yamaguchi
Journal:  Stroke       Date:  2010-07-22       Impact factor: 7.914

2.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.

Authors:  W M Clark; S Wissman; G W Albers; J H Jhamandas; K P Madden; S Hamilton
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

3.  Early administration of tissue-plasminogen activator improves the long-term clinical outcome at 5years after onset.

Authors:  Junya Aoki; Kazumi Kimura; Yuki Sakamoto
Journal:  J Neurol Sci       Date:  2016-01-14       Impact factor: 3.181

4.  Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study.

Authors:  Gregory W Albers; Vincent N Thijs; Lawrence Wechsler; Stephanie Kemp; Gottfried Schlaug; Elaine Skalabrin; Roland Bammer; Wataru Kakuda; Maarten G Lansberg; Ashfaq Shuaib; William Coplin; Scott Hamilton; Michael Moseley; Michael P Marks
Journal:  Ann Neurol       Date:  2006-11       Impact factor: 10.422

5.  Low-dose intravenous recombinant tissue-type plasminogen activator therapy for patients with stroke outside European indications: Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) rtPA Registry.

Authors:  Masatoshi Koga; Yoshiaki Shiokawa; Jyoji Nakagawara; Eisuke Furui; Kazumi Kimura; Hiroshi Yamagami; Yasushi Okada; Yasuhiro Hasegawa; Kazuomi Kario; Satoshi Okuda; Kaoru Endo; Tetsuya Miyagi; Masato Osaki; Kazuo Minematsu; Kazunori Toyoda
Journal:  Stroke       Date:  2011-09-29       Impact factor: 7.914

6.  Acute ischemic stroke and long-term outcome after thrombolysis: nationwide propensity score-matched follow-up study.

Authors:  Marie Louise Schmitz; Claus Z Simonsen; Heidi Hundborg; Hanne Christensen; Karsten Ellemann; Karin Geisler; Helle Iversen; Charlotte Madsen; Mary-Jette Rasmussen; Karsten Vestergaard; Grethe Andersen; Soeren P Johnsen
Journal:  Stroke       Date:  2014-09-04       Impact factor: 7.914

7.  Long-Term Survival After Intravenous Thrombolysis for Ischemic Stroke: A Propensity Score-Matched Cohort With up to 10-Year Follow-Up.

Authors:  Walter Muruet; Anthony Rudd; Charles D A Wolfe; Abdel Douiri
Journal:  Stroke       Date:  2018-02-12       Impact factor: 7.914

8.  Severe Lesions Involving Cortical Cholinergic Pathways Predict Poorer Functional Outcome in Acute Ischemic Stroke.

Authors:  Jian-Feng Qu; Yang-Kun Chen; Gen-Pei Luo; Jiang-Hao Zhao; Huo-Hua Zhong; Han-Peng Yin
Journal:  Stroke       Date:  2018-12       Impact factor: 7.914

9.  Acute Phase Predictors of 6-Month Functional Outcome in Italian Stroke Patients Eligible for In-Hospital Rehabilitation.

Authors:  Marco Franceschini; Stefania Fugazzaro; Maurizio Agosti; Carlotta Sola; Antonio Di Carlo; Lorenzo Cecconi; Salvatore Ferro
Journal:  Am J Phys Med Rehabil       Date:  2018-07       Impact factor: 2.159

10.  Incidence of total stroke, stroke subtypes, and myocardial infarction in the Japanese population: the JMS Cohort Study.

Authors:  Shizukiyo Ishikawa; Kazunori Kayaba; Tadao Gotoh; Naoki Nago; Yosikazu Nakamura; Akizumi Tsutsumi; Eiji Kajii
Journal:  J Epidemiol       Date:  2008-07-07       Impact factor: 3.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.